SAN

79.13

-1.37%↓

UCB

274.1

-0.22%↓

SHL.DE

37.75

+0.05%↑

ARGX

679.4

-0.21%↓

VIE

34.5

-1.4%↓

SAN

79.13

-1.37%↓

UCB

274.1

-0.22%↓

SHL.DE

37.75

+0.05%↑

ARGX

679.4

-0.21%↓

VIE

34.5

-1.4%↓

SAN

79.13

-1.37%↓

UCB

274.1

-0.22%↓

SHL.DE

37.75

+0.05%↑

ARGX

679.4

-0.21%↓

VIE

34.5

-1.4%↓

SAN

79.13

-1.37%↓

UCB

274.1

-0.22%↓

SHL.DE

37.75

+0.05%↑

ARGX

679.4

-0.21%↓

VIE

34.5

-1.4%↓

SAN

79.13

-1.37%↓

UCB

274.1

-0.22%↓

SHL.DE

37.75

+0.05%↑

ARGX

679.4

-0.21%↓

VIE

34.5

-1.4%↓

Search

Vetoquinol SA

Fermé

SecteurSoins de santé

78.7 -1.13

Résumé

Variation du prix de l'action

24h

Actuel

Min

77.5

Max

79.6

Chiffres clés

By Trading Economics

Revenu

25M

Ventes

10M

268M

P/E

Moyenne du Secteur

15.373

66.418

Marge bénéficiaire

9.734

Employés

2,497

EBITDA

252M

301M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+37.16% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-7.1M

928M

Ouverture précédente

79.83

Clôture précédente

78.7

Sentiment de l'Actualité

By Acuity

50%

50%

154 / 348 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bearish Evidence

Vetoquinol SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

13 avr. 2026, 23:25 UTC

Principaux Événements d'Actualité

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13 avr. 2026, 22:45 UTC

Principaux Événements d'Actualité

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13 avr. 2026, 18:03 UTC

Résultats

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13 avr. 2026, 23:58 UTC

Résultats

Review & Preview: Earnings Time -- Barrons.com

13 avr. 2026, 23:49 UTC

Market Talk

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13 avr. 2026, 23:33 UTC

Market Talk
Principaux Événements d'Actualité

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13 avr. 2026, 23:20 UTC

Market Talk

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13 avr. 2026, 23:01 UTC

Résultats

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13 avr. 2026, 23:01 UTC

Résultats

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13 avr. 2026, 23:01 UTC

Résultats

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13 avr. 2026, 22:21 UTC

Acquisitions, Fusions, Rachats

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13 avr. 2026, 21:53 UTC

Résultats

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13 avr. 2026, 21:53 UTC

Résultats

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13 avr. 2026, 21:53 UTC

Résultats

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13 avr. 2026, 21:53 UTC

Résultats

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13 avr. 2026, 21:26 UTC

Principaux Événements d'Actualité

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13 avr. 2026, 21:23 UTC

Résultats

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13 avr. 2026, 21:16 UTC

Résultats

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13 avr. 2026, 20:50 UTC

Market Talk
Principaux Événements d'Actualité

Basic Materials Roundup: Market Talk

13 avr. 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

13 avr. 2026, 20:34 UTC

Résultats

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13 avr. 2026, 20:34 UTC

Résultats

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13 avr. 2026, 20:34 UTC

Résultats

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13 avr. 2026, 19:59 UTC

Market Talk

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13 avr. 2026, 19:50 UTC

Market Talk
Principaux Événements d'Actualité

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13 avr. 2026, 19:27 UTC

Market Talk
Principaux Événements d'Actualité

Correction to Precious Metals Market Talk on April 9

13 avr. 2026, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13 avr. 2026, 18:59 UTC

Market Talk
Principaux Événements d'Actualité

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13 avr. 2026, 18:59 UTC

Market Talk
Principaux Événements d'Actualité

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13 avr. 2026, 18:43 UTC

Market Talk

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Comparaison

Variation de prix

Vetoquinol SA prévision

Objectif de Prix

By TipRanks

37.16% hausse

Prévisions sur 12 Mois

Moyen 110 EUR  37.16%

Haut 110 EUR

Bas 110 EUR

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

1

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

72.6 / 75.1Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

154 / 348Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Vetoquinol SA

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
help-icon Live chat